MRK · News · 20260806N

Product Launch and Transition

Merck & Co., Inc. · 2026-08-06 · Importance 34 · Surprise 42

Merck is using newer products to diversify growth ahead of the expected Keytruda loss of exclusivity. LIPFENDRA, an oral PCSK9 inhibitor, received U.S. FDA approval, while Winrevair showed strong commercial uptake. The company also highlighted the newer subcutaneous Keytruda QLEX formulation as a contributor to oncology growth.

Key facts

• Merck Animal Health awarded $50,000 in scholarships to five veterinary students specializing in poultry health, marking the 11th year of the program and total distributed over $280,000. source